<p>來自 JonesTrading 的分析師 Debanjana Chatterjee 對 EyePoint Pharmaceuticals 維持買入評級，並將目標價定為 43.00 美元。</p>
<h3>TipRanks 網絡星期一促銷</h3>
<ul>
<li>申請 TipRanks Premium 享受 60% 的折扣，獲取數據支持的洞察和研究工具，助您自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據，現在也享受 60% 的折扣。</li>
</ul>
<p>Debanjana Chatterjee 的評級基於對 EyePoint Pharmaceuticals 的良好前景，特別是其濕性年齡相關性黃斑變性（wet AMD）療法 Duravyu，預計將在 2026 年前有關鍵試驗結果發佈。該公司在濕性 AMD 批准方面採取了成熟的監管路徑，這被視為相較於其他採取更創新方法的公司的戰略優勢。</p>
<p>EyePoint 的財務狀況也很強勁，擁有可觀的現金儲備，為其持續和未來的研究與開發活動提供了堅實的基礎。市場動態和濕性 AMD 治療的潛在範式轉變進一步支持了買入評級，因為 EyePoint 的療法可能在滿足該領域未滿足的需求方面發揮重要作用。</p>
<p>在 12 月 9 日發佈的另一份報告中，瑞穗證券也重申了對該股票的買入評級，目標價為 33.00 美元。</p>

EYPT

<p>分析師 Debanjana Chatterjee 來自 JonesTrading，維持對 EyePoint Pharmaceuticals 的買入評級，目標價為 43.00 美元，理由是其有前景的濕性年齡相關性黃斑變性治療藥物 Duravyu 以及強勁的財務狀況。EyePoint 的戰略監管路徑和市場動態支持該評級。瑞穗證券也重申了買入評級，目標價為 33.00 美元</p>

<p>Analyst Debanjana Chatterjee from JonesTrading maintained a Buy rating on EyePoint Pharmaceuticals and keeping the price target at $43.00.</p>
<div class="lb-trans"><p>來自 JonesTrading 的分析師 Debanjana Chatterjee 對 EyePoint Pharmaceuticals 維持買入評級，並將目標價定為 43.00 美元。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 網絡星期一促銷</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>申請 TipRanks Premium 享受 60% 的折扣，獲取數據支持的洞察和研究工具，助您自信投資。</li>
<li>訂閲 TipRanks 的智能投資者精選，通過我們高表現的模型投資組合查看我們的數據，現在也享受 60% 的折扣。</li>
</ul>
</div><p>Debanjana Chatterjee’s rating is based on the promising outlook for EyePoint Pharmaceuticals, particularly with its wet AMD therapy, Duravyu, which is expected to have pivotal trial readouts by 2026. The company has pursued a well-established regulatory path for wet AMD approval, which is seen as a strategic advantage compared to other companies taking more innovative approaches.</p>
<div class="lb-trans"><p>Debanjana Chatterjee 的評級基於對 EyePoint Pharmaceuticals 的良好前景，特別是其濕性年齡相關性黃斑變性（wet AMD）療法 Duravyu，預計將在 2026 年前有關鍵試驗結果發佈。該公司在濕性 AMD 批准方面採取了成熟的監管路徑，這被視為相較於其他採取更創新方法的公司的戰略優勢。</p>
</div><p>EyePoint’s financial position is also strong, with significant cash reserves that provide a solid foundation for its ongoing and future research and development activities. The market dynamics and potential paradigm shifts in wet AMD treatments further support the Buy rating, as EyePoint’s therapies could play a significant role in addressing unmet needs in this space.</p>
<div class="lb-trans"><p>EyePoint 的財務狀況也很強勁，擁有可觀的現金儲備，為其持續和未來的研究與開發活動提供了堅實的基礎。市場動態和濕性 AMD 治療的潛在範式轉變進一步支持了買入評級，因為 EyePoint 的療法可能在滿足該領域未滿足的需求方面發揮重要作用。</p>
</div><p>In another report released on December 9, Mizuho Securities also reiterated a Buy rating on the stock with a $33.00 price target.</p>
<div class="lb-trans"><p>在 12 月 9 日發佈的另一份報告中，瑞穗證券也重申了對該股票的買入評級，目標價為 33.00 美元。</p>
</div>

買入建議：EyePoint 製藥的戰略定位及其有前景的濕性年齡相關性黃斑變性（AMD）療法